Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
Dr. Giuseppe Mancia
Prof. Guido Grassi
The fixed combination of an ACE-inhibitor (perindopril, 2mg) and a diuretic agent (indapamide, 0.625mg) on top of standard treatment in more than 11.000 diabetic in 20 countries of the blood pressure lowering arm of ADVANCE, has had since 2001, a favourable impact on their elevated cardiovascular risk profile. According to the trial's author’s opinion, this treatment should be made mandatory in diabetic patients because it is practical and affordable safe, well tolerated and requires little monitoring and is effective in the majority of patients. We believe it may become the routine therapeutic approach in the future for patients with diabetes mellitus even when blood pressure is not elevated. New ESC-ESH guidelines speak in favour of initiating antihypertensive treatment in diabetic patients even when blood pressure is still in the high-normal ranges.
ADVANCE (Action in Diabetes and Vascular Disease-PreterAx and DiamicroN Controlled Evaluation) is an ongoing large-scale prospective randomised clinical trial aimed at investigating the effects of blood pressure lowering and intensive blood glucose control in high risk diabetic patients on major macrovascular and microvascular events. Results of the blood pressure lowering treatment study have been published in the LANCET in June (1), while the glucose lowering arm is just coming to a conclusion and data will be presented at the American Diabetes Association Conference in San Francisco at the beginning of June.
A large number of epidemiological and clinical studies have shown that in patients with diabetes mellitus, hypertension is an important risk factor for cardiovascular and renal disease, including macro- and microvascular complications such as nephropathy. This has been shown for example in the:
Altogether these findings strongly support the notion that the presence of hypertension has a prognostic adverse impact on diabetic patients.
Evidence from several studies has shown that the risk associated with high blood pressure in diabetic patient can be reduced with appropriate therapeutic strategies. This has been shown in the :
Despite these encouraging data, information collected in clinical practice have shown that blood pressure control is poor in uncomplicated hypertensive patients and that this is particularly the case in subjects in whom high blood pressure is associated with diabetes (5). This implies that one of the future therapeutic challenges in the field of antihypertensive treatment will be the achievement of an optimal blood pressure control.
The ADVANCE Trial is the largest-ever study aimed at investigating the effects of a treatment based on the fixed combination of an ACE-inhibitor (perindopril, 2mg) and a diuretic agent (indapamide, 0.625mg) on macrovascular and microvascular complications and deaths. The main features of ADVANCE can be summarised as follows.
The results can be summarised as follows.
Thus, the fixed combination treatment used in the ADVANCE trial and administered on top of all other drugs (antihypertensive drugs, statins, aspirin and blood glucose lowering agents) had a favourable impact on the elevated cardiovascular risk profile of the diabetic patient. This makes this therapeutic strategy mandatory in diabetic patients because, according to the ADVANCE Author’s opinion (1), is
In commenting the ADVANCE Trial results, an obvious question should be addressed, namely whether the study data imply that a fixed combination of perindopril / indapamide should became a routine therapeutic approach for patients with diabetes mellitus, even when blood pressure is not elevated. An analysis of the ADVANCE data suggest that this is the case, also considering that the recent Guidelines for the Management of Hypertension, jointly issued by the European Society of Hypertension / European Society of Cardiology, speak in favour of initiating antihypertensive treatment in diabetic patients even when blood pressure is still in the high-normal range (7).
Along with the blood pressure lowering arm completed in June 2007 with results published in The Lancet (1), ADVANCE also includes the blood glucose lowering arm which is still an ongoing investigation.
An effective glycaemic control is of great relevance in clinical practice.
Figure 1. Combined primary outcome and mortality curves in patients of the ADVANCE Trial randomised to placebo or Perindopril/Indapamide combination treatment. Figure modified from Ref 1.
Figure 2. Percent reduction in micro and macrovasular events, coronary heart disease (CHD), stroke, renal disease and new microalbuminuria (MA) in the ADVANCE Trial. Data from Ref. 1
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
1. Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-840. 2. Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J Jr, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol. 2005;16:3027-3037. 3. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. British Med Journal. 2000;321:412-419. 4. Mancia G, Omboni S, Parati G, Clement DL, Haley WE, Rahman SN, Hoogma RP. Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. J Hypertens 2001;19:1755-1763. 5. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens. 2002;20:1461-464. 6. Chalmers J, Joshi R, Patel A. Advances in reducing the burden of vascular disease in type 2 diabetes. Clin Exp Pharmacol Physiol. 2008;35:434-437. 7. Mancia G, De Backer G, Dominiczak A, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187. 8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853. 9. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486-494. 10. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
11. Goff DC Jr, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG; ACCORD Study Group. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99(12A):4i-20i. 12. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation. J Hypertens Suppl. 2001;19:S21-28. 13. ACCORD news conference. 14. Press release: ADVANCE does not confirm ACCORD results.
*Prof. G. Grassi and **Prof G. Mancia Milan , Italy *Past-Chairman ESC Working Group Hypertension and the Heart, **Past-President European Society of Hypertension (ESH), Past-President International Society of Hypertension, Chairman of the ESH/ESC Task Force for the management of hypertension.
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved